autologous oxidized tumor cell lysate vaccine

OC-L is an autologous cancer vaccine composed of oxidized tumor cell lysates, specifically developed for the treatment of advanced epithelial ovarian, fallopian tube, and primary peritoneal cancers. The vaccine is produced by harvesting a patient's own tumor cells and treating them with hypochlorous acid (HOCl). This oxidation process enhances the immunogenicity of the tumor cells by inducing immunogenic cell death and facilitating the processing and presentation of a broad spectrum of tumor-associated antigens and neoantigens by dendritic cells. Developed at the Abramson Cancer Center of the University of Pennsylvania, OC-L is typically administered as part of a multi-adjuvant regimen including sargramostim (GM-CSF), Montanide ISA 51, and poly-ICLC (a TLR3 agonist) to prime and expand tumor-specific T-cell responses.

Other names

oxidized tumor cell lysate vaccineautologous oxidized ovarian cancer cell lysate vaccine